<DOC>
	<DOC>NCT01881217</DOC>
	<brief_summary>An open-label, non-randomized, Phase I dose-escalation study designed to assess the safety, tolerability, pharmacokinetics(PK) /pharmacodynamics( PD) and tumor response profile of BAY1179470 in subjects with advanced, refractory solid tumors</brief_summary>
	<brief_title>First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subjects with advanced, histologically or cytologically confirmed solid tumors refractory to any standard therapy or have no standard therapy available or subjects actively refuse any treatment which would be regarded standard Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1 and a life expectancy of at least 3 months At least moderate FGFR2 expression in the tumor tissue from archival samples is confirmed: for subjects in additional cohort History of severe allergic reactions to monoclonal antibody therapy Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mm Hg and/or diastolic blood pressure &gt; 90 mmHg, despite optimal medical management Any condition that is unstable or could jeopardize the safety of the subject and his / her compliance in the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Advanced, refractory solid tumors</keyword>
	<keyword>FGFR2</keyword>
</DOC>